褪黑素对新冠肺炎ICU住院患者疗效的评价：一项双盲随机临床试验

Q3 Medicine

Vacunas Pub Date : 2025-01-01 DOI:10.1016/j.vacun.2024.09.004

Mahmoud Ganjifard , Shokouh Ghafari , Adeleh Sahebnasagh , Mahboubeh Esmaeili , Ali Reza Amirabadizadeh , Azadeh Ebrahimzadeh , Parvin Askari , Razieh Avan

{"title":"褪黑素对新冠肺炎ICU住院患者疗效的评价：一项双盲随机临床试验","authors":"Mahmoud Ganjifard , Shokouh Ghafari , Adeleh Sahebnasagh , Mahboubeh Esmaeili , Ali Reza Amirabadizadeh , Azadeh Ebrahimzadeh , Parvin Askari , Razieh Avan","doi":"10.1016/j.vacun.2024.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This research aims to examine the efficacy of melatonin as an adjuvant therapeutic agent for COVID-19 patients in the intensive care unit.</div></div><div><h3>Methods</h3><div>A randomized, double-blind, placebo-controlled investigation was conducted on a group of hospitalized COVID-19 patients. Individuals were allocated into 2 groups: one group received a combination of 18 mg of melatonin and standard treatment for 14 days; the other group received a placebo in addition to standard treatment. Patients were evaluated at the beginning of the study as well as the 7th and 15th days to analyze changes in clinical symptoms, P/F ratio, and inflammatory markers.</div></div><div><h3>Results</h3><div>The study included patients with an average age of 57.80±17.96 years, with an equal gender representation. The average length of hospital stay was 19.83±4.45 days. Hypertension and diabetes were commonly observed comorbidities. There were no significant differences in the demographic characteristics between the 2 groups (<em>P</em>  >.05).</div></div><div><h3>Conclusion</h3><div>Our study's findings suggested that melatonin is unlikely to significantly affect the clinical status of COVID-19 patients.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100377"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the effect of melatonin on patients with COVID-19 admitted to ICU: A double-blind randomized clinical trial\",\"authors\":\"Mahmoud Ganjifard , Shokouh Ghafari , Adeleh Sahebnasagh , Mahboubeh Esmaeili , Ali Reza Amirabadizadeh , Azadeh Ebrahimzadeh , Parvin Askari , Razieh Avan\",\"doi\":\"10.1016/j.vacun.2024.09.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and objectives</h3><div>This research aims to examine the efficacy of melatonin as an adjuvant therapeutic agent for COVID-19 patients in the intensive care unit.</div></div><div><h3>Methods</h3><div>A randomized, double-blind, placebo-controlled investigation was conducted on a group of hospitalized COVID-19 patients. Individuals were allocated into 2 groups: one group received a combination of 18 mg of melatonin and standard treatment for 14 days; the other group received a placebo in addition to standard treatment. Patients were evaluated at the beginning of the study as well as the 7th and 15th days to analyze changes in clinical symptoms, P/F ratio, and inflammatory markers.</div></div><div><h3>Results</h3><div>The study included patients with an average age of 57.80±17.96 years, with an equal gender representation. The average length of hospital stay was 19.83±4.45 days. Hypertension and diabetes were commonly observed comorbidities. There were no significant differences in the demographic characteristics between the 2 groups (<em>P</em>  >.05).</div></div><div><h3>Conclusion</h3><div>Our study's findings suggested that melatonin is unlikely to significantly affect the clinical status of COVID-19 patients.</div></div>\",\"PeriodicalId\":53407,\"journal\":{\"name\":\"Vacunas\",\"volume\":\"26 1\",\"pages\":\"Article 100377\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vacunas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1576988724000967\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988724000967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

本研究旨在探讨褪黑素作为辅助治疗剂对重症监护病房COVID-19患者的疗效。方法采用随机、双盲、安慰剂对照的方法对1组新冠肺炎住院患者进行调查。个体被分为两组：一组接受18 毫克褪黑激素和14 天的标准治疗；另一组在标准治疗的基础上接受安慰剂治疗。在研究开始时以及第7天和第15天对患者进行评估，以分析临床症状、P/F比率和炎症标志物的变化。结果入组患者平均年龄57.80±17.96 岁，性别平等。平均住院时间为19.83±4.45 d。高血压和糖尿病是常见的合并症。两组患者人口学特征差异无统计学意义(P >；. 05)。此外，两组在临床症状改善、死亡率、不良反应和各种血液标志物方面无显著差异(P >；. 05)。结论本研究结果提示，褪黑素对COVID-19患者的临床状态影响不大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of the effect of melatonin on patients with COVID-19 admitted to ICU: A double-blind randomized clinical trial

Introduction and objectives

This research aims to examine the efficacy of melatonin as an adjuvant therapeutic agent for COVID-19 patients in the intensive care unit.

Methods

A randomized, double-blind, placebo-controlled investigation was conducted on a group of hospitalized COVID-19 patients. Individuals were allocated into 2 groups: one group received a combination of 18 mg of melatonin and standard treatment for 14 days; the other group received a placebo in addition to standard treatment. Patients were evaluated at the beginning of the study as well as the 7th and 15th days to analyze changes in clinical symptoms, P/F ratio, and inflammatory markers.

Results

The study included patients with an average age of 57.80 ± 17.96 years, with an equal gender representation. The average length of hospital stay was 19.83 ± 4.45 days. Hypertension and diabetes were commonly observed comorbidities. There were no significant differences in the demographic characteristics between the 2 groups (P > .05). Additionally, there were no significant distinctions between the 2 groups in terms of clinical symptom improvement, mortality rate, adverse effects, and various blood markers (P > .05).

Conclusion

Our study's findings suggested that melatonin is unlikely to significantly affect the clinical status of COVID-19 patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vacunas Medicine-Infectious Diseases

CiteScore

3.90

自引率

0.00%

发文量

138

审稿时长

62 days

期刊介绍： Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.